RBX2660 Clinical Trials
Rebiotix conducted two clinical trials of lead Microbiota Restoration Therapy RBX2660 targeted at recurrent Clostridium difficile (C. diff.) infection in conjunction with the U.S. Food and Drug Administration under an Independent New Drug Application.
Study: PUNCH CD
- Phase 2 prospective multi-center, open-label study with 6-month follow-up
- Primary objective: Assess the safety of RBX2660
- Secondary objective: Efficacy defined as no CDI recurrence at 8 weeks
- Forty patients were enrolled at 11 centers in the US; a total of 31 patients completed 6-month follow-up.
- Overall efficacy was 87.1% (27/31).
- Safety: Most commonly reported AEs were mild to moderate diarrhea, flatulence, abdominal pain/cramping and constipation and were self-limiting.
- Twenty serious AEs were reported in 7 patients; none were related to RBX2660 or its administration.
- RBX2660 demonstrated a satisfactory safety profile in a Phase 2 study targeted at recurrent CDI which included a rigorous, independent assessment of AEs.
- Overall efficacy of 87.1% is in line with previously reported results.
Study: PUNCH CD 2
- Phase 2B, prospective, multi-center randomized double-blind, placebo-controlled with 2-year follow-up
- Primary efficacy objective: Assess the efficacy of RBX2660 vs. placebo defined as no CDI recurrence at 8 weeks
- Primary safety objective: Assess the safety of RBX2660
- A total of 120 patients enrolled at 21 sites in the U.S. and Canada
- Patients were randomized into 3 treatment arms
Study: PUNCH Open Label
- Prospective, multicenter, open-label, controlled Phase 2 study
- Primary efficacy endpoint involved a comparison of patients treated with RBX2660 to a closely matched set of antibiotic only treated historical controls through 56 days
- 31 active treatment sites and four control sites in the U.S. and Canada.
- 132 RBX2660 and 110 historical control subjects were included in this topline analysis